Cipla Quarterly Results
Cipla quarterly results. In Mar 2026, Cipla (CIPLA) reported revenue ₹6,612 Cr and net profit ₹543 Cr — revenue -4.0% YoY. Review CIPLA earnings valuation to evaluate earnings-based valuation against sector peers.
CIPLA Quarterly Results — Revenue, Profit & EPS Highlights
Cipla latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check Cipla marketcap in USD to track the company's total market size over time.
- Revenue of ₹6,612 Cr in Mar 2026 (-9.3% vs Jun 2026, -4.0% vs Mar 2025)
- Net Profit of ₹543 Cr in Mar 2026 (-30.9% vs Jun 2026, -55.3% vs Mar 2025)
- EBITDA of ₹1,026 Cr in Mar 2026 (-24.6% vs Jun 2026)
- Operating Margin of 14.0% in Mar 2026 (-2.0pp vs Jun 2026)
- Earnings Per Share of ₹6.87 in Mar 2026 (-29.7% vs Jun 2026)
Cipla Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CIPLA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 6,612 | 7,288 | 7,716 | 6,887 | 7,096 | -9.3% | -4.0% |
| Net Profit (₹ Cr) | 543 | 786 | 1,353 | 1,214 | 1,292 | - | - |
| EBITDA (₹ Cr) | 1,026 | 1,361 | 2,022 | 1,695 | 1,916 | - | - |
| EPS (₹) | 6.87 | 9.77 | 16.73 | 15.13 | 16.07 | - | - |
| Operating Margin (%) | 14.0% | 16.0% | 24.0% | 21.0% | 24.0% | - | - |
CIPLA Share Price Trend — 1-Year Movement Across Quarterly Results
Cipla 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit CIPLA share price screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CIPLA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Cipla latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹421,995.00 Cr | 1758.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 155.6 |
|
Divis Laboratories
Mar 2026 |
₹241,231.30 Cr | 9162.0 | 2,986 | 751 | -5.0% | - | 25.2% | 323.6 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4615.3 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 401.0 |
|
Laurus Labs
Mar 2026 |
₹111,790.60 Cr | 2002.5 | 1,823 | 282 | -10.5% | - | 15.5% | 387.3 |
|
Zydus Life Science
Mar 2026 |
₹111,111.95 Cr | 1135.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 89.7 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores